Introduction {#cesec10}
============

Bariatric surgery has been used for decades to treat patients with severe obesity. In 2016, global guidelines established through the Diabetes Surgery Summit (DSS), an international consensus conference series, formally recognised gastrointestinal surgery as a standard therapy for type 2 diabetes; this practice is known as metabolic surgery.[@bib1] During the coronavirus disease 2019 (COVID-19) outbreak, under unprecedented pressure to free up inpatient capacity, and because of intraoperative risks for viral contagion among patients and staff, hospitals worldwide have been obliged to postpone most elective operations, including bariatric and metabolic surgery. Increased hazards of severe COVID-19 complications in patients with obesity, type 2 diabetes, or both,[@bib2], [@bib3], [@bib4], [@bib5] further support the rationale for a pause in elective surgery during the peak of the pandemic.

The return to normal services will be gradual, with surgeons competing for reduced capacity to address a backlog of elective procedures. Hence, access to bariatric and metabolic surgery will continue to be constrained. Given the uncertainty regarding the effects and duration of the COVID-19 outbreak, combined with the progressive nature of obesity, diabetes, and related conditions, delaying bariatric and metabolic surgery could increase the risks for morbidity and mortality in surgical candidates. The risk of harm, however, is variable among individuals, depending on the type and severity of disease and their indications for bariatric and metabolic surgery. The traditional, weight-centric criteria for patient selection in bariatric surgery, which are still commonly used today, do not reflect severity of disease,[@bib6] and they therefore cannot be used to prioritise treatment based on actual clinical needs. Furthermore, physical distancing policies and continued lockdowns might limit adherence to lifestyle interventions, worsening metabolic deterioration among candidates for bariatric and metabolic surgery. Additionally, reduced access to non-urgent care during the COVID-19 pandemic might impede postoperative monitoring for potential surgical and nutritional complications.

A clear and urgent need therefore exists for strategies to mitigate harm to patients during and after the COVID-19 pandemic. These approaches should include non-surgical interventions to optimise metabolic and weight control in patients awaiting surgery, telemedicine protocols for postoperative surveillance, and use of appropriate criteria to triage surgical candidates during a foreseeable period of reduced capacity for elective surgery. To address these issues, the DSS[@bib1] organisers directed a group of international experts to assess the effect of the COVID-19 pandemic on candidates for surgical treatment of obesity and type 2 diabetes. Our specific aim was to develop criteria to help prioritise bariatric and metabolic surgery for when elective surgery is resumed and beyond.

Elective surgery: definitions and prioritisation {#cesec20}
================================================

Surgery ameliorates a wide range of conditions and diseases, both acute and chronic. Emergency surgery is required when acute problems pose immediate threat to life, organs, or limbs, and must be done without delay. Elective surgery refers to operations that can be planned and scheduled in advance. These procedures, however, are not optional, because they can have important, life-changing implications. When access to elective surgery is reduced, doctors should prioritise patients with the greatest need or with a greater risk of harm from delayed treatment. In some health-care systems, elective surgery is categorised into urgent, semi-urgent, or non-urgent.[@bib7], [@bib8] Urgent elective surgery is required within 30 days for conditions that might deteriorate quickly. Semi-urgent conditions are those that, although not likely to deteriorate quickly, could reasonably cause severe pain or dysfunction or further harm if delayed beyond 3 months. Non-urgent elective surgery is planned for conditions that are unlikely to cause substantial discomfort, dysfunction, or harm if treated within 1 year.

Although some complications from bariatric and metabolic operations can require emergency surgical treatment (eg, haemorrhage, leak, or intestinal obstruction), most bariatric and metabolic procedures represent genuine elective surgery. To date, however, no consensus exists for criteria to identify urgent, semi-urgent, or non-urgent indications in bariatric and metabolic surgery on the basis of the type and severity of patients\' conditions.

Delaying elective surgery during the peak of the COVID-19 pandemic {#cesec30}
==================================================================

There are many reasons why most bariatric and metabolic operations should be suspended during the most intense phase of the COVID-19 pandemic, including infection risks among patients and staff, factors inherent to the operations, and increased hazards of severe COVID-19 complications among patients with obesity or type 2 diabetes.

Procedure-related risks {#cesec40}
-----------------------

Laparoscopic surgery involves aerosol-generating techniques such as carbon dioxide, pneumoperitoneum, electrocautery, and ultrasonic shearing. These techniques could easily increase the risk of viral contagion for staff,[@bib9], [@bib10] including with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Upper gastrointestinal endoscopy (another aerosol-producing procedure) is also commonly done before bariatric and metabolic surgery. Patients undergoing major surgery are at risk of life-threatening inflammatory complications such as infection (including from viruses), the systemic inflammatory response syndrome, and sepsis.[@bib11]

Although there is no conclusive evidence that laparoscopy or upper endoscopy can promote COVID-19 transmission, postponing elective metabolic and bariatric interventions during the acute phase of the COVID-19 outbreak seems sensible, except for urgent revisional surgery or emergency endoscopic interventions for complications (eg, haemorrhage, stoma stenosis, or leaks).

Despite the potential for a higher risk of contagion, the laparoscopic approach in bariatric and metabolic surgery is associated with substantial benefits compared with traditional open surgery, especially in patients with severe obesity. These benefits include lower rates of mortality and complications (including pulmonary and procedural), and shorter hospital stays.[@bib12], [@bib13] For these reasons, laparoscopic access should remain the preferred approach over open techniques when elective bariatric and metabolic surgery resumes. Appropriate personal protective equipment should be used, however, given the increased risk of SARS-CoV-2 infection for staff.

Risks of severe COVID-19 complications in obesity and type 2 diabetes {#cesec50}
---------------------------------------------------------------------

Obesity increases the risk of complications from viral respiratory infections. During the 2009 influenza H1N1 pandemic in California, 91% of people who died had obesity, and higher BMI was associated with mortality.[@bib14] In patients admitted to intensive care for SARS-CoV-2, class 2--3 obesity (BMI \>35 kg/m^2^) is an independent risk factor for disease severity.[@bib5] Similarly, patients with diabetes have augmented risk for severe COVID-19 and mortality.[@bib2], [@bib3], [@bib4], [@bib5]

Several mechanisms have been suggested to increase the risk of complications from viral infections in obesity and type 2 diabetes, including low-grade chronic inflammation with overproduction of proinflammatory cytokines, reduced natural killer cell number and activity, and impaired antigen-stimulation responses.[@bib15], [@bib16], [@bib17] Another factor that might have a role in the relationship between obesity, diabetes, and increased risk for complications is that SARS-CoV-2 enters host cells by binding to the angiotensin-converting-enzyme 2 (ACE2) receptor. ACE2 transforms angiotensin 2 to angiotensin,[@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20] thereby reducing vasoconstriction, sodium retention, inflammation, and metabolic degeneration.[@bib21] Chronic hyperglycaemia downregulates ACE2 expression,[@bib22] and further reduction of ACE2 during COVID-19 infection could contribute to hyperinflammation and respiratory failure in patients with type 2 diabetes.[@bib23] People with obesity are also prone to hypoventilation syndrome, cardiovascular disease,[@bib24] heart failure,[@bib25] and other conditions that could increase the risk of COVID-19 mortality.

When elective bariatric and metabolic surgery resumes, the pandemic will be contained, but SARS-CoV-2 will probably still circulate in the population. Given the risks of severe complications from COVID-19 in patients with obesity and type 2 diabetes, we recommend that COVID-19 screening should be mandatory preoperatively for patients considering bariatric and metabolic surgery.

Risk of disease progression from delayed operations {#cesec60}
===================================================

Class 2--3 obesity and type 2 diabetes, the most common indications for bariatric and metabolic surgery, are associated with reduced quality of life and increased morbidity and mortality. Their ability to cause life-threatening complications, however, varies depending on the severity or stage of disease and the burden of comorbidities. The degree of harm from delaying metabolic and bariatric surgery depends on each patient\'s condition, the surgical efficacy at different stages of disease, and the availability and effectiveness of non-surgical therapies to control disease progression while awaiting surgery. Understanding the prognostic factors of morbidity and mortality in obesity and type 2 diabetes can help to define criteria for surgical prioritisation.

Prognosis and prognostic factors of type 2 diabetes {#cesec70}
---------------------------------------------------

Diabetes is a major cause of morbidity and death, including from cardiovascular, renal, neurological, and retinal complications. Approximately two-thirds of people with diabetes die of cardiovascular disease, with a relative risk 1·8--2·6 times greater than in people without diabetes.[@bib26] The biological progression of type 2 diabetes, characterised by declining β-cell function and continuing insulin resistance, is manifested clinically by deteriorations in multiple parameters, including HbA~1c~, fasting, and postprandial glucose levels. The UK prospective diabetes study[@bib27] reported significant associations between hyperglycaemia and development of diabetes complications or death, and a 21% risk reduction for any diabetes-related endpoint with each 1% absolute HbA~1c~ reduction.

Factors beyond hyperglycaemia can also influence type 2 diabetes prognosis. In the TRIAD study,[@bib28], [@bib29] predictors of all-cause mortality at 4 years and 8 years of study follow-up included older age, male sex, non-Hispanic white race, lower education and income, longer duration of diabetes, lower BMI, hypertension, macrovascular disease, retinopathy, nephropathy, and neuropathy. Among the specific predictors of cardiovascular mortality were also treatment with insulin (with or without oral medication), higher LDL cholesterol, history of nephropathy, transient ischaemic attack, stroke, angina, myocardial infarction, coronary artery and peripheral vascular disease, and use of antihypertensive or cholesterol-lowering medications.

Factors predicting obesity-related morbidity and mortality {#cesec80}
----------------------------------------------------------

Obesity increases the risks of many other illnesses, including diabetes, hypertension, dyslipidaemia, liver disease, coronary artery and cerebrovascular disease, many cancers, cholelithiasis, infertility, psychosocial dysfunction, osteoarthritis, chronic kidney disease, and now also COVID-19. Together, these complications powerfully reduce quality of life and exacerbate obesity-associated mortality. Even before COVID-19, obesity reduced life expectancy by 5--20 years.[@bib30] Notably, higher all-cause mortality is associated with obesity class 2 (BMI 35--39·9 kg/m^2^) and 3 (BMI ≥40 kg/m^2^), corresponding to candidates for bariatric surgery, but not with class 1 obesity (BMI 30--34·9 kg/m^2^).[@bib31]

Obesity hypoventilation syndrome and obesity-associated heart failure substantially increase mortality. Obesity hypoventilation syndrome represents the combination of obesity and chronic daytime hypercapnia.[@bib32], [@bib33] The prevalence of obesity hypoventilation syndrome is highest among patients with a BMI of more than 50 kg/m^2^.[@bib34] Mortality from untreated obesity hypoventilation syndrome can be as high as 24% at 1·5--2 years after diagnosis.[@bib35] Obesity heart failure is associated with increased mortality, and for each 5-unit increase in BMI, heart failure-related mortality increases by 1·4 times.[@bib36]

Since BMI alone does not reflect obesity-related mortality and morbidity, staging systems such as the King\'s Obesity Criteria[@bib37] and Edmonton Obesity Staging System (EOSS)[@bib38] have been developed to assess individual patients\' risk on the basis of evidence of subclinical, established, or end-stage comorbidities.[@bib39] Retrospective application of EOSS to data from the National Health and Nutrition Examination Survey showed that patients in stages 2--4 of EOSS have increased all-cause mortality compared with stages 0 or 1. This finding supports the idea that the presence, type, and severity of obesity-related complications, in addition to BMI,[@bib39] should inform decision making about the prioritisation of treatment, especially surgery.

Non-alcoholic fatty liver disease {#cesec90}
---------------------------------

Non-alcoholic fatty liver disease is characterised by excess hepatic fat. Its more aggressive form, non-alcoholic steatohepatitis, includes hepatocyte injury, inflammation, and fibrosis.[@bib40], [@bib41], [@bib42] These two conditions affect 20--25% of the western population, with rates rising worldwide.[@bib40], [@bib43] 66% of patients with obesity and diabetes have non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.[@bib44], [@bib45]

Non-alcoholic steatohepatitis can lead to cirrhosis (in 15--20% of cases), liver failure, or hepatocellular carcinoma.[@bib46] Beyond liver-related mortality, non-alcoholic steatohepatitis can substantially increase microvascular and macrovascular complications, and cardiovascular mortality in patients with obesity and type 2 diabetes.[@bib40], [@bib41], [@bib42], [@bib43], [@bib47], [@bib48] Non-randomised trials suggest that Roux-en-Y gastric bypass resolves the histological features of non-alcoholic steatohepatitis in up to 80% of patients.[@bib49], [@bib50]

Effects of bariatric and metabolic surgery {#cesec100}
------------------------------------------

Randomised clinical trials and observational studies show that in patients with all classes of obesity, bariatric and metabolic surgery promotes greater long-term weight loss than the best available non-surgical interventions, regardless of the operation chosen.[@bib47], [@bib51], [@bib52], [@bib53] Multiple observational studies also indicate that bariatric and metabolic surgery lowers long-term risk of all-cause mortality compared with matched non-surgical patients.[@bib54], [@bib55], [@bib56], [@bib57], [@bib58], [@bib59] Data from eight observational studies involving a total of 635 642 patients suggest that bariatric and metabolic surgery is associated with a reduced risk of all types of cancer (odds ratio \[OR\]=0·72; 95% CI 0·59--0·87) and obesity-associated cancer (OR=0·55; 95% CI 0·31--0·96).[@bib60], [@bib61], [@bib62] Without exception, each of the 29 all-cause mortality studies published to date shows that patients who have bariatric and metabolic surgery live longer than matched non-surgical controls.[@bib54], [@bib55], [@bib56], [@bib57], [@bib58], [@bib59], [@bib63], [@bib64]

Concerning type 2 diabetes, at least 12 randomised controlled trials comparing bariatric and metabolic surgery with conventional diabetes therapies (ie, lifestyle plus medication) in patients with type 2 diabetes show that surgery is superior for control of hyperglycaemia, reduction of cardiovascular and overall mortality risk, improvement in quality of life, and reduction in risk of renal complications.[@bib1], [@bib65], [@bib66] The safety of bariatric and metabolic surgery compares favourably with that of most elective operations, including hysterectomy, cholecystectomy, and knee replacement. Surgical treatments for diabetes are highly cost-effective, with the cost per quality-adjusted life-year ranging between US\$3200 and \$13 000.[@bib1], [@bib65], [@bib67]

Based on this evidence, DSS guidelines, which have been formally endorsed by 56 worldwide medical or scientific organisations and recognised by payers worldwide, recommend the consideration of bariatric and metabolic surgery for appropriate candidates (including those with only class 1 obesity), who do not achieve adequate glycaemic control with medical therapy.[@bib1]

Health and economic costs of delaying bariatric and metabolic surgery {#cesec110}
---------------------------------------------------------------------

The delay of bariatric and metabolic surgery that is occurring due to COVID-19 will augment the burden of disease among surgical candidates. This increase will particularly affect patients with type 2 diabetes, given that metabolic surgery causes remission of hyperglycaemia in most cases.[@bib65] The likelihood of hyperglycaemia remission, however, depends upon how soon an operation is done during the natural history of diabetes. Algorithms designed to predict surgical remission (eg, DiaRem-2, AD-DiaRem, DiaBetter, and ABCD)[@bib68], [@bib69], [@bib70], [@bib71] consistently show that longstanding disease is one of the most powerful indicators of failure to achieve this benefit.[@bib72] Remission rates drop off notably after 10 years of diabetes. Moreover, the SOS study[@bib73] reported substantially lower type 2 diabetes remission among patients with only 4 years of known disease than in those with 2 years of known disease. Thus, delaying metabolic surgery reduces the chances of diabetes remission.

Delayed metabolic surgery might cause even greater harm to patients with type 2 diabetes who are at higher risk of microvascular and macrovascular complications and mortality, especially when medications and lifestyle interventions are not achieving adequate metabolic control. Patients without diabetes but with severe respiratory (obesity hypoventilation syndrome), cardiac, or renal complications of obesity, and individuals for whom weight reduction is crucial to advancing time-sensitive and life-saving treatments (eg, organ transplants) also have greater risks of harm from delaying bariatric and metabolic surgery.

Patients with surgically remediable metabolic diseases, especially diabetes, incur more health-care costs per day than do those without these conditions. All studies that compared costs for 1--5 years between surgical and non-surgical patients found that pharmacy expenses decrease substantially after bariatric and metabolic surgery compared with matched non-surgical patients,[@bib74], [@bib75], [@bib76], [@bib77], [@bib78] primarily due to lower diabetes medication costs.[@bib69] Hence, metabolic surgery decreases daily health-care costs, especially for patients requiring multidrug therapy. The longer surgery is delayed for these patients, the less cost-saving it becomes.

Management of surgical candidates and postoperative follow-up in times of COVID-19 {#cesec120}
==================================================================================

Various non-surgical options can be used to mitigate the harm from delaying bariatric and metabolic surgery and to manage patients who have had surgery ([panel 1](#box1){ref-type="boxed-text"} ). Regarding the need to optimise glycaemic control in patients with type 2 diabetes, especially those with advanced microvascular or macrovascular complications,[@bib79] we considered available evidence of pharmacological strategies that promote weight loss, such as glucagon-like peptide-1 receptor agonists (GLP-1RA) or sodium/glucose cotransporter 2 (SGLT-2) inhibitors, or both.[@bib80] GLP-1RAs reduce HbA~1c~ by about 1%[@bib81] while promoting clinically relevant weight loss.[@bib82] SGLT-2 inhibitors, however, might be contraindicated with COVID-19, because of concerns about potential subclinical vascular congestion and risk of acute metabolic decompensation associated with these drugs.[@bib83] Panel 1Diabetes Surgery Summit recommendations for managing bariatric and metabolic surgical candidates and postoperative patients during the coronavirus disease 2019 pandemic**Non-surgical options to mitigate harm from delaying surgery**•Glycaemic control should be optimised in patients awaiting metabolic surgery for type 2 diabetes, especially for those with advanced microvascular or macrovascular complications; this is desirable to prepare for surgery and also in case of severe acute respiratory syndrome coronavirus 2 infection•In patients who do not achieve glycaemic targets with lifestyle modifications and metformin, the addition of a glucagon-like peptide-1 receptor agonist (GLP-1RA) or sodium/glucose cotransporter 2 (SGLT-2) inhibitor, or both, can advance the combined goals of improving metabolic control and causing weight loss or limiting weight gain; use of SGLT-2 inhibitors, however, is not recommended in the case of acute coronavirus disease 2019 (COVID-19) infection because of concerns about potential subclinical vascular congestion and risk of acute metabolic decompensation associated with these drugs•For patients with multiple weight-responsive comorbidities who face prolonged waiting times for surgery, dietary or pharmacological interventions for weight control might become necessary•Diets with higher protein content and lower glycaemic index can be effective and should be considered•Among patients already taking weight-loss medications, efforts should be made to continue the drug(s) until surgery is scheduled, since rapid weight regain is predictable when they are discontinued•In countries where weight-loss medications (eg, phentermine, orlistat, GLP-1RAs, naltrexone--bupropion, and phentermine--topiramate) are accessible, clinicians could consider their use when weight loss or weight maintenance is important, such as for patients with multiple weight-responsive comorbidities**Management of patients who have had surgery**•Telemedicine strategies that are supervised by specialist bariatric and metabolic surgery providers should be used•In people with persistent or recurrent type 2 diabetes after surgery, weight-reducing diabetes medications (eg, GLP-1RAs) should be considered; weight maintenance should also be encouraged in patients with type 2 diabetes remission to mitigate risk of disease recurrence•There is insufficient evidence to justify deviations from current evidence-based recommendations for postoperative nutritional care in patients who have had bariatric and metabolic surgery•To minimise risk of nutrition-related complications, providers should engage with patients at the same intervals as in current guidelines•Clinical signs (eg, weight, visual changes, rash, weakness, oedema or anasarca, and neuropsychiatric signs), and symptoms (eg, nausea, tingling, bowel-habit changes, and fatigue) of nutritional deficiency must be assessed during virtual clinic sessions•Routine laboratory tests (eg, albumin, thiamine, B12, vitamin A, vitamin D, iron, and calcium) should not be deferred but obtained at standard intervals, particularly for patients who had operations with greater risk of nutrient malabsorption, such as long-limb diversionary procedures•Urgent face-to-face meetings and laboratory tests are mandated when symptoms suggest severe biochemical deficiencies or surgical complications (eg, intestinal obstruction or acute cholecystitis)**Preparation for surgery and surgical technique**•Misconceptions and stigma about obesity and bariatric and metabolic surgery might further penalise candidates for surgical treatment of obesity and diabetes in times of limited resources; clinicians, policy makers, and hospital managers should recognise the seriousness of the diseases that require metabolic and bariatric surgery and ensure that these operations are not further delayed•Given the risks of severe complications from COVID-19 in patients with obesity and type 2 diabetes, COVID-19 screening should be mandatory preoperatively for patients considering bariatric and metabolic surgery•Despite the potential higher risk of contagion for staff, the risk and benefit of a laparoscopic approach remain favourable for patients and should be preferred over the use of open techniques•Appropriate personal protective equipment should be used as recommended by professional bodies and public health agencies to minimise risk for staff and operators

We also considered available data regarding the efficacy of dietary or pharmacological interventions for weight loss,[@bib84], [@bib85], [@bib86], [@bib87], [@bib88] or both, as a strategy to achieve weight loss or weight maintenance in patients with multiple weight-responsive comorbidities who face prolonged waiting times for bariatric and metabolic surgery. Regarding strategies to maximise surgical outcomes in patients who have already had surgery, our recommendations are based on results from studies investigating the efficacy of pharmacological approaches in people with persistent or recurrent type 2 diabetes after surgery. Among these individuals, a recent study[@bib89] showed that the GLP-1RA liraglutide can reduce HbA~1c~ by 1·2%, with up to 5% additional weight loss. We reviewed existing evidence-based recommendations for postoperative nutritional care[@bib79] to define safe and pragmatic methods of virtual consultation by telemedicine ([panel 1](#box1){ref-type="boxed-text"}).

Priorities in resuming elective bariatric and metabolic procedures {#cesec130}
==================================================================

Even before the COVID-19 pandemic, metabolic and bariatric surgery was underused for many reasons, including misconceptions and stigma about obesity and bariatric surgery.[@bib90] Such barriers might further penalise candidates for this surgery in times of limited resources. Given the seriousness of the diseases that require metabolic and bariatric surgery, clinicians, hospital managers, and policy makers should ensure that these operations are not further delayed because of the widespread misconception that they are a last resort.[@bib90]

Eventually, the COVID-19 crisis will abate, and elective operations will resume, leaving an enormous backlog of patients who would benefit from bariatric and metabolic surgery. How should we prioritise whom to serve first with limited resources? At a broad level, the answer is simple. If patients are well enough to be safe surgical candidates, preference should be afforded to those with the greatest risk of morbidity and mortality from their disease, if it is probable that this risk can be reduced by surgery. This logic would apply, for instance, to many surgical candidates with poorly controlled type 2 diabetes or substantial metabolic, respiratory, or cardiovascular disease.

Traditional BMI-centric criteria for patient selection, however, tend to skew access to bariatric and metabolic surgery in the opposite direction. Despite strong evidence that surgery achieves its greatest health benefits among patients with type 2 diabetes, a minority of those who have such operations have preoperative type 2 diabetes or cardiometabolic disease.[@bib91] Furthermore, in many publicly funded health-care systems (eg, UK National Health Service), candidates for bariatric and metabolic surgery are currently placed on a single elective surgery waiting list, regardless of their indication. Priority is established largely on a first-come first-served basis, rather than on clinical need. This approach is comparable to putting all colorectal surgery candidates on the same waiting list with similar priority, regardless of whether their diagnosis is cancer or benign neoplasia. A strong need therefore exists for clinically sound criteria to help prioritise access to surgery in times of pandemics with limited resources. These criteria can also inform future waiting list management and decision making about the structure of surgical services.

Principles of prioritisation for bariatric and metabolic surgery {#cesec140}
----------------------------------------------------------------

The prioritisation of any elective operation should seek to facilitate access according to clinical need, maximise equity of access, and minimise the harm from delayed access. We have adapted previous categorisations of elective surgery[@bib7] to define an objective prioritisation system reflecting these principles for bariatric and metabolic operations ([panel 2](#box2){ref-type="boxed-text"} ; [figure](#fig1){ref-type="fig"} ).Panel 2Categories of access to bariatric and metabolic surgery**Urgent access: surgery within 30 days**Patient\'s condition is associated with one of the following:•Conditions with potential to deteriorate quickly•Severe symptoms or dysfunction•Examples include severe dysphagia or vomiting from anastomotic stenosis, symptomatic internal hernia, severe nutritional deficiencies, or acute band-related complications**Expedited access: surgery within 90 days**Patient\'s conditions are not likely to deteriorate quickly but are associated with one of the following:•Substantial risk of morbidity or mortality•Reasonable risk of harm or reduced efficacy of treatment if surgery is delayed beyond 90 days•Complex medical regimens or insulin requirement•Weight loss, metabolic improvement, or both, are required to allow other time-sensitive treatments (eg, organ transplants or orthopaedic surgery)**Standard access: surgery after 90 days**•Patient\'s conditions are unlikely to deteriorate within 6 months•Only mild dysfunction or symptoms•Delaying surgical treatment beyond 90 days is unlikely to significantly reduce effectiveness of surgeryFigureExamples of conditions that warrant expedited access to bariatric and metabolic surgeryAHA=American Heart Association.

Given the factors contributing to morbidity and mortality in obesity and type 2 diabetes, surgical prioritisation should be based on disease-specific considerations. For patients with type 2 diabetes, we suggest that surgery be prioritised for patients at increased risk of morbidity and mortality. This risk would be indicated by poor glycaemic control despite maximal medical therapy, use of insulin, previous cardiovascular disease, albuminuria and chronic kidney disease, non-alcoholic steatohepatitis, or multiple cardiometabolic comorbidities.[@bib28] Insulin use is a meaningful prioritisation criterion because it correlates with increased cardiovascular mortality[@bib28] and reduced quality of life.[@bib92] Moreover, metabolic surgery reduces or abolishes the need for insulin in most patients.[@bib1], [@bib47], [@bib52] To mitigate the risk of substantially reducing treatment efficacy, we suggest prioritising surgery in patients with more than 5 years of diabetes. This suggestion is based on evidence that individuals with shorter diabetes duration have greater chances of achieving disease remission,[@bib92] whereas type 2 diabetes duration of 8--10 years remits far less often postoperatively.[@bib1], [@bib65], [@bib93]

The severity of obesity-associated symptoms (eg, mobility issues or joint pain as a consequence of extremely high BMI, regardless of comorbidities) must also be considered when establishing priorities. Equally important is the effect of obesity-related conditions that increase morbidity and mortality (eg, obesity hypoventilation syndrome, chronic kidney disease, or severe obstructive sleep apnoea).[@bib38] The availability of non-surgical options that slow disease progression (ie, pharmacological diabetes treatments achieving adequate glycaemic control) reduces need for prioritisation. Expedited access to surgery should also be considered when bariatric and metabolic operations are used as adjuvant therapy to enable other time-sensitive treatments that are made unfeasible or unsafe by excess weight, poor metabolic control, or both ([figure](#fig1){ref-type="fig"}).

Many candidates for bariatric and metabolic surgery are at high risk of morbidity and mortality from comorbid conditions. For these patients, access to surgical treatment should be prioritised on the basis of disease-focused clinical needs, rather than primarily on BMI, to mitigate harm from delaying surgery. This approach is especially needed in periods in which access to surgery is reduced, as in the current COVID-19 pandemic. Societal crises often spur developments that provide benefits long after the storm passes. Disease-oriented, medically meaningful strategies to triage patients seeking metabolic surgery after the COVID-19 crisis should help prioritise patients in more urgent need, both now and long into the future.

Search strategy and selection criteria {#cesec150}
======================================

We did a rapid narrative literature review for this Personal View. For references about the effect of viral infections including coronavirus disease 2019 (COVID-19) on diabetes, obesity, and laparoscopic surgery, we searched PubMed for articles in English published between Jan 1, 2002, and April 10, 2020. We used combinations of terms such as "SARS", "H1N1", "coronavirus", "COVID-19", "SARS-CoV-2", "diabetes", "obesity", "BMI" "laparoscopy", "endoscopy", "severe acute respiratory syndrome", "acute respiratory distress syndrome", and "co-morbidities".We also reviewed recent guidelines from professional organisations and public health agencies about elective surgery and the COVID-19 pandemic. For evidence about the benefits of bariatric and metabolic surgery, the predicting factors of morbidity and mortality from type 2 diabetes, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis, and the classification of elective surgery, we reviewed recently published systematic reviews and consensus statements by major scientific societies and relevant individual articles cited in these documents.Members of the expert panel were selected on the basis of their previous participation in the Diabetes Surgery Summit series and their relevant expertise. Additional experts were also invited to join the group and provide complementary expertise or ensure global representation, or both. A subgroup of the expert panel did a first appraisal of the evidence and draft recommendations, and they generated the first draft of the report, synthetising the literature review in response to each specific query. The entire expert group then engaged in online discussion to further appraise the evidence and refine the final consensus recommendations.
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